An Open-Label Trial of Donepezil in Fragile X Syndrome

Trial ID or NCT#

NCT00220584

Status

not recruiting iconNOT RECRUITING

Purpose

Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability. Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that specific brain regions using the neurochemical, acetylcholine, show significantly reduced activation during learning. Since donepezil is a medication that enhances acetylcholine function in the brain, the purpose of this study is to determine if donepezil has any beneficial effect on behavior or cognition in subjects with fragile X syndrome.

Official Title

An Open-Label Trial of Donepezil in Fragile X Syndrome

Eligibility Criteria

Ages Eligible for Study: Older than 14 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Confirmed genetic diagnosis of fragile X syndrome 2. Age e 14 3. Verbal IQ e 60
Exclusion Criteria:
  1. 1. Currently taking any anticholinergic medications, tricyclic antidepressant medications, or diphenhydramine. 2. Presence of cardiac disease or bradycardia (< 60 beats/minute) at initial evaluation.
View All Criteria
Show Less

Investigator(s)

Allan L. Reiss

View on ClinicalTrials.gov